Abstract
Serum sickness is a type III hypersensitivity reaction. The classic symptoms are malaise, rash, fever, arthralgias, and lymphadenopathy that occur within 8–12 days of antigen exposure and sooner if it is a re-exposure. The diagnosis is based on clinical signs and symptoms with supporting laboratory tests that suggest an inflammatory response in the body with increased immune complex production. This is a self-limiting disease and therapy for serum sickness is primarily supportive to alleviate symptoms using anti-inflammatory medications. Prognosis is very good once the inciting agent has been stopped and rarely does one have permanent end-organ damage as a result of serum sickness. With future research and investigation, there is hope for enhanced risk stratification and earlier detection.